TR200301971T4 - Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri - Google Patents

Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri

Info

Publication number
TR200301971T4
TR200301971T4 TR2003/01971T TR200301971T TR200301971T4 TR 200301971 T4 TR200301971 T4 TR 200301971T4 TR 2003/01971 T TR2003/01971 T TR 2003/01971T TR 200301971 T TR200301971 T TR 200301971T TR 200301971 T4 TR200301971 T4 TR 200301971T4
Authority
TR
Turkey
Prior art keywords
partial
agonists
complete
heterorocyclic
adenosine derivatives
Prior art date
Application number
TR2003/01971T
Other languages
English (en)
Turkish (tr)
Inventor
A. Zablocki Jeff
P. Palle Venkate
Varkhed Kar Vaibhav
Belardinelli Lu�Z
N. Ibrahim Prabha
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200301971T4 publication Critical patent/TR200301971T4/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
TR2003/01971T 1999-12-03 2000-12-01 Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri TR200301971T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
TR200301971T4 true TR200301971T4 (tr) 2004-01-21

Family

ID=23803455

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2003/01971T TR200301971T4 (tr) 1999-12-03 2000-12-01 Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri
TR2001/03129T TR200103129T2 (tr) 1999-12-03 2000-12-01 Kısmi ya da tam A1 agonistleri-N6 heterosiklik 5'-tio ikameli adenosin türevleri.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/03129T TR200103129T2 (tr) 1999-12-03 2000-12-01 Kısmi ya da tam A1 agonistleri-N6 heterosiklik 5'-tio ikameli adenosin türevleri.

Country Status (25)

Country Link
US (2) US6605597B1 (enExample)
EP (1) EP1233973B1 (enExample)
JP (1) JP4021195B2 (enExample)
KR (1) KR100484988B1 (enExample)
CN (1) CN1152042C (enExample)
AR (1) AR029199A1 (enExample)
AT (1) ATE254133T1 (enExample)
AU (3) AU4138701A (enExample)
BR (1) BR0016126A (enExample)
CA (1) CA2389264C (enExample)
CZ (1) CZ20013705A3 (enExample)
DE (1) DE60006576T2 (enExample)
DK (1) DK1233973T3 (enExample)
ES (1) ES2208437T3 (enExample)
HK (1) HK1047941A1 (enExample)
HU (1) HUP0500455A2 (enExample)
IL (1) IL145903A (enExample)
MX (1) MXPA01011113A (enExample)
NO (1) NO20015373L (enExample)
NZ (1) NZ514777A (enExample)
PT (1) PT1233973E (enExample)
TR (2) TR200301971T4 (enExample)
TW (1) TWI249536B (enExample)
WO (2) WO2001040243A2 (enExample)
ZA (1) ZA200204380B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US6946449B2 (en) * 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
PL372145A1 (en) * 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
RU2332220C2 (ru) * 2002-04-18 2008-08-27 Си Ви Терапьютикс, Инк. Способ снижения частоты сердечных сокращений, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом
AU2003259264A1 (en) * 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
AU2004284098B2 (en) 2003-10-21 2009-07-16 Inspire Pharmaceuticals, Inc. Tetrahydro-furo [3,4-d] dioxole compounds and compositions and method for inhibiting platelet aggregation
US7749980B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
DK1682537T3 (da) * 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
ES2530780T3 (es) * 2005-05-17 2015-03-05 Sarcode Bioscience Inc Composiciones y métodos para el tratamiento de trastornos oculares
JP5203214B2 (ja) * 2005-11-30 2013-06-05 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CN101511366B (zh) * 2006-09-01 2011-12-28 吉利德帕洛阿尔托股份有限公司 在心肌显像方法期间用于增加患者耐受性的方法和组合物
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
CA3105972A1 (en) 2007-10-19 2009-04-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
JP2011521896A (ja) * 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
EP0764639A4 (en) * 1994-06-09 1997-10-01 Ss Pharmaceutical Co 4-CHINOLINONE DERIVATIVE OR ITS SALT
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
NO20015373L (no) 2001-11-29
JP2003516325A (ja) 2003-05-13
CZ20013705A3 (cs) 2002-04-17
WO2001040243A3 (en) 2001-12-13
EP1233973B1 (en) 2003-11-12
AU7938301A (en) 2002-03-21
KR20030032907A (ko) 2003-04-26
AU4138701A (en) 2001-06-12
ZA200204380B (en) 2003-06-25
PT1233973E (pt) 2004-02-27
WO2001040243A2 (en) 2001-06-07
US6605597B1 (en) 2003-08-12
US20050054605A1 (en) 2005-03-10
CN1152042C (zh) 2004-06-02
DE60006576D1 (de) 2003-12-18
ES2208437T3 (es) 2004-06-16
HUP0500455A2 (hu) 2005-08-29
JP4021195B2 (ja) 2007-12-12
BR0016126A (pt) 2002-08-06
CA2389264A1 (en) 2001-06-07
KR100484988B1 (ko) 2005-04-22
HK1047941A1 (zh) 2003-03-14
NO20015373D0 (no) 2001-11-02
DK1233973T3 (da) 2004-02-16
NZ514777A (en) 2004-01-30
IL145903A (en) 2006-04-10
AR029199A1 (es) 2003-06-18
CA2389264C (en) 2007-03-06
TR200103129T2 (tr) 2002-10-21
EP1233973A1 (en) 2002-08-28
CN1378550A (zh) 2002-11-06
TWI249536B (en) 2006-02-21
AU761029B2 (en) 2003-05-29
MXPA01011113A (es) 2002-06-04
DE60006576T2 (de) 2004-09-16
ATE254133T1 (de) 2003-11-15
WO2001040246A1 (en) 2001-06-07
AU1811701A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
TR200301971T4 (tr) Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri
TR200201470T2 (tr) N6 heterosiklik 8-modifiye adenosin türevleri.
SE0003984D0 (sv) Adenosin A3-receptormodulatorer
NO20010446L (no) Substituert anilidforbindelser og metoder
TR200000015T2 (tr) Bileşikler ve metodlar
EE04499B1 (et) A1-adenosiiniretseptori agonistid, nende valmistamismeetod ja kasutamine
ATE242259T1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
TR199901721T2 (xx) Merkezi kanabinoid resept�r antagonistlerinin i�tah ayarlanmas�nda kullan�lmas�.
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
DE59814072D1 (de) Verwendung von Agonisten des zentralen Cannabinoid-Rezeptors CB1
ATE234322T1 (de) A1 adenosin rezeptor agonisten und antagonisten
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
DE68923048D1 (de) Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
DK0463592T3 (da) 2,4- og 2,5-substituerede pyridin-N-oxider, fremgangsmåder til deres fremstilling samt deres anvendelse
DE59806335D1 (de) Vorrichtung zum sicheren, formschlüssigen Montieren, Ausrichten und Fixieren von Karosserieteilen
TR200301062T2 (tr) Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri
ES2168384T3 (es) Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos para el sistema cardiovascular.
AU5614198A (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
TR200003356T2 (tr) Kabergolin ve pramipeksol: yeni kullanım biçimleri ve birlikte kullanılmaları.
ATE273390T1 (de) Säugertier edg-7 rezeptor homologen
DK1223930T3 (da) Behandling af dyskinesi
BR0015736A (pt) Derivados de adenosina modificados por n6 heterocìclico 8
TR199802324T2 (xx) Penis ereksiyon fonksiyonu bozukluğu tedavisi için alfa bloke ajanlarının ve özellikle de moksisilit ve/veya türevlerinin balanik transmukoza rotası üzerinden kullanımı.
BR9915589A (pt) Uso de derivados de azabicicloalcano n-substituìdo